Marco Meglio, Assistant Managing Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at mmeglio@neurologylive.com
Promise Behind Stem Cell Approaches to Treat Epilepsy: Jonathon Parker, MD, PhD
December 10th 2024The assistant professor of neurosurgery and neuroscience at Mayo Clinic Arizona provided context on the potential of regenerative therapies like stem cells to restore neural function in patients with epilepsy. [WATCH TIME: 3 minutes]
Testing Begins for RELIEV-CM2 Study of ShiraTronics Neuromodulation Device in Chronic Migraine
December 5th 2024Early data from the pilot RELIEV-CM trial showed significant reductions in headache and migraine days, with 56% of patients showing a 50% reduction in symptoms at 4 weeks, and 100% at 12 weeks.
Empowering Patients: Exploring Self-Administration of Rozanolixizumab for Myasthenia Gravis
December 3rd 2024Rachana K. Gandhi Mehta, MBBS, an assistant professor of neurology at Wake Forest School of Medicine, discussed a new, innovative trial assessing the therapeutic potential of self-administered subcutaneous rozanolixizumab as a treatment for myasthenia gravis.
Brenig Therapeutics Initiates First-in-Human Trial of LRRK2 Inhibitor BT-267 for Parkinson Disease
December 3rd 2024To date, BT-267 shows strong potential as a best-in-class LRRK2 inhibitor for Parkinson disease, with a superior safety profile, excellent pharmacokinetics, and innovative development leveraging advanced technologies and biomarker modeling.
AL002 Falls Short in Phase 2 INVOKE-2 Trial of Early Alzheimer Disease
November 26th 2024AL002 did not meet the primary endpoint of slowing Alzheimer's clinical progression, as measured by the Clinical Dementia Rating Sum of Boxes and showed no treatment effects on secondary clinical and functional endpoints.